Literature DB >> 22020283

Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B.

Julian P Vivian1, Renee C Duncan, Richard Berry, Geraldine M O'Connor, Hugh H Reid, Travis Beddoe, Stephanie Gras, Philippa M Saunders, Maya A Olshina, Jacqueline M L Widjaja, Christopher M Harpur, Jie Lin, Sebastien M Maloveste, David A Price, Bernard A P Lafont, Daniel W McVicar, Craig S Clements, Andrew G Brooks, Jamie Rossjohn.   

Abstract

Members of the killer cell immunoglobulin-like receptor (KIR) family, a large group of polymorphic receptors expressed on natural killer (NK) cells, recognize particular peptide-laden human leukocyte antigen (pHLA) class I molecules and have a pivotal role in innate immune responses. Allelic variation and extensive polymorphism within the three-domain KIR family (KIR3D, domains D0-D1-D2) affects pHLA binding specificity and is linked to the control of viral replication and the treatment outcome of certain haematological malignancies. Here we describe the structure of a human KIR3DL1 receptor bound to HLA-B*5701 complexed with a self-peptide. KIR3DL1 clamped around the carboxy-terminal end of the HLA-B*5701 antigen-binding cleft, resulting in two discontinuous footprints on the pHLA. First, the D0 domain, a distinguishing feature of the KIR3D family, extended towards β2-microglobulin and abutted a region of the HLA molecule with limited polymorphism, thereby acting as an 'innate HLA sensor' domain. Second, whereas the D2-HLA-B*5701 interface exhibited a high degree of complementarity, the D1-pHLA-B*5701 contacts were suboptimal and accommodated a degree of sequence variation both within the peptide and the polymorphic region of the HLA molecule. Although the two-domain KIR (KIR2D) and KIR3DL1 docked similarly onto HLA-C and HLA-B respectively, the corresponding D1-mediated interactions differed markedly, thereby providing insight into the specificity of KIR3DL1 for discrete HLA-A and HLA-B allotypes. Collectively, in association with extensive mutagenesis studies at the KIR3DL1-pHLA-B*5701 interface, we provide a framework for understanding the intricate interplay between peptide variability, KIR3D and HLA polymorphism in determining the specificity requirements of this essential innate interaction that is conserved across primate species.
© 2011 Macmillan Publishers Limited. All rights reserved

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020283      PMCID: PMC3723390          DOI: 10.1038/nature10517

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  29 in total

1.  Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties.

Authors:  K Maenaka; T Juji; T Nakayama; J R Wyer; G F Gao; T Maenaka; N R Zaccai; A Kikuchi; T Yabe; K Tokunaga; K Tadokoro; D I Stuart; E Y Jones; P A van der Merwe
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

2.  Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation.

Authors:  William H Carr; David B Rosen; Hisashi Arase; Douglas F Nixon; Jakob Michaelsson; Lewis L Lanier
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

3.  Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells.

Authors:  M Peruzzi; K C Parker; E O Long; M S Malnati
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

4.  KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand.

Authors:  William Henry Carr; Marcelo Jorge Pando; Peter Parham
Journal:  J Immunol       Date:  2005-10-15       Impact factor: 5.422

5.  Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells.

Authors:  M Colonna; J Samaridis
Journal:  Science       Date:  1995-04-21       Impact factor: 47.728

Review 6.  The genomic context of natural killer receptor extended gene families.

Authors:  J Trowsdale; R Barten; A Haude; C A Stewart; S Beck; M J Wilson
Journal:  Immunol Rev       Date:  2001-06       Impact factor: 12.988

7.  Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.

Authors:  Diana Chessman; Lyudmila Kostenko; Tessa Lethborg; Anthony W Purcell; Nicholas A Williamson; Zhenjun Chen; Lars Kjer-Nielsen; Nicole A Mifsud; Brian D Tait; Rhonda Holdsworth; Coral Ann Almeida; David Nolan; Whitney A Macdonald; Julia K Archbold; Anthony D Kellerher; Debbie Marriott; Simon Mallal; Mandvi Bharadwaj; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

8.  Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1.

Authors:  Bharati Sanjanwala; Monia Draghi; Paul J Norman; Lisbeth A Guethlein; Peter Parham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  A time- and cost-efficient system for high-level protein production in mammalian cells.

Authors:  A Radu Aricescu; Weixian Lu; E Yvonne Jones
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-09-19

10.  The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer.

Authors:  Salim I Khakoo; Ron Geller; Sunny Shin; Jomaquai A Jenkins; Peter Parham
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

View more
  113 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

2.  Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition.

Authors:  William F Hawse; Brian E Gloor; Cory M Ayres; Kevin Kho; Elizabeth Nuter; Brian M Baker
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

Review 3.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

4.  KIR3DL1 genetic diversity and phenotypic variation in the Chinese Han population.

Authors:  S D Tao; Y M He; Y L Ying; J He; F M Zhu; H J Lv
Journal:  Genes Immun       Date:  2013-10-31       Impact factor: 2.676

Review 5.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

6.  KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Behçet Disease.

Authors:  Harry Petrushkin; Paul J Norman; Emma Lougee; Peter Parham; Graham R Wallace; Miles R Stanford; Farida Fortune
Journal:  J Immunol       Date:  2019-08-12       Impact factor: 5.422

7.  Host-specific adaptation of HIV-1 subtype B in the Japanese population.

Authors:  Takayuki Chikata; Jonathan M Carlson; Yoshiko Tamura; Mohamed Ali Borghan; Takuya Naruto; Masao Hashimoto; Hayato Murakoshi; Anh Q Le; Simon Mallal; Mina John; Hiroyuki Gatanaga; Shinichi Oka; Zabrina L Brumme; Masafumi Takiguchi
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11.

Authors:  Jingxian Liu; Ziwei Xiao; Hui Ling Ko; Meixin Shen; Ee Chee Ren
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 9.  The killer-cell immunoglobulin-like receptors of macaques.

Authors:  Benjamin N Bimber; David T Evans
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

Review 10.  Co-evolution of MHC class I and variable NK cell receptors in placental mammals.

Authors:  Lisbeth A Guethlein; Paul J Norman; Hugo G Hilton; Peter Parham
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.